Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu

Date : 11/23/2018 @ 4:50PM
Source :InvestorsHub NewsWire
Stock : Phoenix Life Sciences International Ltd. (PLSI)
Quote : 0.4488  0.0 (0.00%) @ 1:03PM

Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15( d )
of the Securities Exchange Act
 
November 1, 2018
Date of Report (Date of Earliest Event Reported)
 
Phoenix Life Sciences International Limited.
(Exact name of registrant as specified in its charter)
 

 

Nevada   333-167275   46-0525378
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification Number)
         

 

3000 Lawrence Street
Denver, CO 80205
1.720.699.7222 or Investor Relations +1.888.717.5655

 (Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices) 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
 
   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      
 

 
 


PHOENIX LIFE SCIENCE INTERNATIONAL LIMITED
Form 8-K
Current Report
 
 

  ITEM 7.01 REGULATION FD DISCLOSURE

 

On November 1, 2018, the Company’s Board of Directors announced that the Company’s stock symbol had been formally changed from MJMD to PLSI, and that the Company had completed its consolidation of businesses to form an international Cannabis Company. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.
 
On November 13, 2018, the Company’s Board of Directors announced that it has retired its Series C Preferred Stock, convertible debt, and has cancelled its series A and B Preferred Stock. A copy of the press release is attached hereto as Exhibit 99.2. The information in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.
 
On November 14, 2018, the Company’s Board of Directors announced that it has received an import certificate from the Republic of Vanuatu’s Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials. A copy of the press release is attached hereto as Exhibit 99.3. The information in this Item 7.01 and the exhibit attached hereto are furnished to, but not filed with, the Securities and Exchange Commission.
 
 

  ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS


 
(d)        
Exhibits. 
 

Exhibit  
Number Description of Exhibit
99.1 Press Release issued November 1, 2018.
99.2 Press Release issued November 13, 2018.
99.3 Press Release issued November 14, 2018.

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

         
  Phoenix Life Science International Limited
  
Date: November 23, 2018 By:  /s/ Martin Tindall
    Martin Tindall
    Chief Executive Officer

 

 
 


Phoenix Life Sciences International Limited 8-K
 
Exhibit 99.1
 

Phoenix Life Sciences International Receives Approval for Name Change, Symbol Change, and Completion of Consolidation of Businesses
 
DENVER – November 2, 2018 – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced it has completed the last stages the consolidation of businesses and received approval from the Financial Industry Regulatory Authority (“FINRA”) of the corporate action completing its name change and change of stock symbol.
 
Phoenix Life Sciences International Limited will now trade under the stock symbol PLSI.
 
“After five years of planning and hard work, we could not be more excited to have completed this consolidation to build a world changing organization,” said Martin Tindall, CEO of Phoenix Life Sciences International. “This marks the end of what has been a long transitional period for our company and the beginning of a new chapter of opportunity for Phoenix Life. We have made incredible progress over the past months towards our goal of creating a truly international healthcare organization. Our focus on creating global supply of pharmaceutical and nutraceutical products derived from medical cannabis and other botanical compounds targeted towards treating patients across the world with a range of diseases makes me truly proud.”
 
The company has recently announced some of the following milestones:
 

  - Completion of merger including retiring all convertible notes
  - Appointment of new Board of Directors and executive team
  - Received approval to establish operations in the country and manufacture botanical pharmaceutical products
  - Medical Advisory Council adds Diabetes Director

 
Tindall continued, “Unlike other companies that are focused on retail or limited markets, our vision is to bring cannabinoid-based treatments to a global audience through government-supported healthcare systems. Starting in the South Pacific, we plan to create a comprehensive supply chain of cannabinoid-based pharmaceutical products that healthcare systems across the world can utilize to improve the health of their people.”
 
For more information about Phoenix Life, visit https://www.plsi.co/.
 
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.

 
 

FORWARD-LOOKING STATEMENTS
 
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
 
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
 
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.
 
LEGAL DISCLOSURE
 
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
 
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
 
Media Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089
 

 
Exhibit 99.2
 

Phoenix Life Sciences International Announces Significant Retirement of Convertible Debt and Elimination of Outstanding Preferred Shares
DENVER , Nov. 13, 2018 (GLOBE NEWSWIRE) — Phoenix Life Sciences International Limited (“Phoenix Life”) (OTC: PLSI), an international adaptive healthcare solutions company, today announced that it has retired additional convertible debt, positioning the company with no more outstanding preferred shares or debt that is subject to conversion.
As a part of the implementation of its fiscal policy aimed at bringing shareholders value and forwarding the company’s mission of creating a global platform for plant-based pharmaceuticals, including bringing medical cannabis products into the mainstream of healthcare, the company has retired its outstanding Series C debt and canceled its Series A and B.
“To operate under the umbrella company Phoenix Life Sciences International, we executed the consolidation of various entities and focused on eliminating as much expensive debt as possible,” said Martin Tindall, Chief Executive Officer of Phoenix Life Sciences International. “Many companies must deal with this issue in later stages of their growth. We are confident that addressing these types of fiscal issues ahead of reaching larger milestones in the ramp up of our product offering is crucial in building a solid fiscal structure for the open markets. We are proud that we were able to achieve this now and focus our attention on our many global healthcare initiatives.”
The company has recently announced multiple milestones in its progress including:

  Completion of merger including retiring all convertible notes
  Appointment of new Board of Directors and executive team
  Received approval to establish operations in the country and manufacture botanical pharmaceutical products
  Medical Advisory Council added Diabetes Director

 
Currently, Phoenix Life is working with the government of the Republic of Vanuatu to target the treatment of diabetes with its cannabis-derived medications. The company plans to utilize a vertically-integrated supply chain model and to springboard distribution throughout the Australian and South Pacific markets, as well as to 30 or more of the countries that have approved medical cannabis.
For more information about Phoenix Life, please visit  https://www.plsi.co/ .
 
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive global healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.

 

 

 


FORWARD-LOOKING STATEMENTS
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
 
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.
LEGAL DISCLOSURE
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail:  investor.relations@phoenixlife.co

 
Media Contact: 
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
1-858-283-4005

 
 

Phoenix Life Sciences International Limited 8-K
 
Exhibit 99.3
 

Phoenix Life Sciences Receives Import Certificate for Cannabis Diabetes Drug from the Republic of Vanuatu
 
DENVER -- November 07, 2018 -- Phoenix Life Sciences International Limited (OTCMarkets: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatu’s Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials.
 
“With this certificate, we look forward to playing a pivotal role in decreasing the size of the global diabetes epidemic,” said Phoenix Life Sciences International CEO Martin Tindall. “The Republic of Vanuatu just took its first steps to legalize medical cannabis throughout the nation, and we are thrilled to be at the forefront of the industry during this historic time.”
 
Phoenix Life can now import its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials for its first 1,000 patients.
 
In the Republic of Vanuatu, a South Pacific island nation comprised of roughly 80 islands, about 13 percent of the population has diabetes. That translates to about 35,000 of the 265,000 residents, making diabetes the largest cost to the nation’s healthcare system. Phoenix Metabolic has the potential to significantly decrease Vanuatu’s yearly cost of diabetes treatments while providing a natural, safer alternative to traditional pharmaceutical medications.
 
"This certificate is the first step in transforming the health of an entire island nation based on a comprehensive, scientific approach to modern illness and disease prevention," said Dr. Philip Blair, Diabetes Director of the Phoenix Life Sciences International Medical Advisory Council.
 
Phoenix Life utilizes a vertically-integrated operation to produce its medical cannabis pharmaceutical products and ensure maximum efficacy. The company aims to partner with the single-payer healthcare systems of both established and emerging economies to conduct medical studies on cannabis for diabetes and establish programs for diabetes patients to receive the company's botanical products.
 
For more information on Phoenix Life, please visit https://plsi.co/ .
 
###

 
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited (OTCMarkets: PLSI) is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
 
FORWARD-LOOKING STATEMENTS
 
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
 
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
 
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S. markets.
 
LEGAL DISCLOSURE
 
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
 
 
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
 
Media Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089


 

Phoenix Life Sciences (USOTC:PLSI)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Phoenix Life Sciences Charts.

Phoenix Life Sciences (USOTC:PLSI)
Intraday Stock Chart

Today : Thursday 12 December 2019

Click Here for more Phoenix Life Sciences Charts.

Latest PLSI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.